{"id":59766,"date":"2022-01-12T14:09:00","date_gmt":"2022-01-12T07:09:00","guid":{"rendered":"https:\/\/www.xinwengao.com\/cn\/pr\/2022011214090059766"},"modified":"2022-01-12T18:05:37","modified_gmt":"2022-01-12T10:05:37","slug":"%e5%88%9b%e8%83%9c%e9%9b%86%e5%9b%a2%e5%b0%86%e5%9c%a8asco-gi%e5%92%8cigcc%e5%9b%bd%e9%99%85%e8%83%83%e7%99%8c%e5%a4%a7%e4%bc%9a%e5%85%ac%e5%b8%83%e4%b8%a4%e9%a1%b9tst001%e4%b8%b4%e5%ba%8a%e8%af%95","status":"publish","type":"post","link":"https:\/\/www.xinwengao.com\/cn\/pr\/2022011214090059766","title":{"rendered":"\u521b\u80dc\u96c6\u56e2\u5c06\u5728ASCO GI\u548cIGCC\u56fd\u9645\u80c3\u764c\u5927\u4f1a\u516c\u5e03\u4e24\u9879TST001\u4e34\u5e8a\u8bd5\u9a8c\u8fdb\u5c55"},"content":{"rendered":"

\u82cf\u5dde2022\u5e741\u670812\u65e5 \/\u7f8e\u901a\u793e\/ — \u521b\u80dc\u96c6\u56e2\uff0806628.HK\uff09\uff0c\u4e00\u5bb6\u5177\u5907\u751f\u7269\u836f\u53d1\u73b0\u3001\u7814\u53d1\u3001\u5de5\u827a\u5f00\u53d1\u548c\u751f\u4ea7\u5168\u6d41\u7a0b\u6574\u5408\u80fd\u529b\u7684\u4e34\u5e8a\u9636\u6bb5\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\uff0c\u5ba3\u5e03TST001\u7f8e\u56fdI\u671f\u4e34\u5e8a\u8bd5\u9a8c\u5c06\u4e8e2022\u5e741\u670820-22\u65e5\u5728\u65e7\u91d1\u5c71\u4e3e\u529e\u7684\u7f8e\u56fd\u4e34\u5e8a\u80bf\u7624\u5b66\u4f1a\u80c3\u80a0\u9053\u80bf\u7624\u7814\u8ba8\u4f1a(ASCO GI)\u4e0a\u901a\u8fc7Trial in Progress (TiP) \u6d77\u62a5\u7684\u65b9\u5f0f\u5c55\u793a\u3002TST001\u4e2d\u56fdI\u671f\u4e34\u5e8a\u6570\u636e\u5c06\u4e8e2022\u5e743\u67086-9\u65e5\u5728\u4f11\u65af\u987f\u4e3e\u529e\u7684\u56fd\u9645\u80c3\u764c\u5927\u4f1a\uff08IGCC\uff09\u4e0a\u4ee5\u6d77\u62a5\u7684\u5f62\u5f0f\u516c\u5e03\u3002<\/p>\n

\u6d77\u62a5\u5c55\u793a
\u7f8e\u56fd\u4e34\u5e8a\u80bf\u7624\u5b66\u4f1a\u80c3\u80a0\u9053\u80bf\u7624\u7814\u8ba8\u4f1a\uff08ASCO GI\uff09<\/span>
\u6458\u8981\u6807\u9898\uff1aA Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of TST001 in Patients with Locally Advanced or Metastatic Solid Tumors
\u4e00\u9879\u5728\u5c40\u90e8\u665a\u671f\u6216\u8f6c\u79fb\u6027\u5b9e\u4f53\u7624\u60a3\u8005\u4e2d\u8bc4\u4f30TST001\u5b89\u5168\u6027\u3001\u8010\u53d7\u6027\u548c\u836f\u4ee3\u52a8\u529b\u5b66\u7684I\u671f\u4e34\u5e8a\u8bd5\u9a8c
\u6458\u8981\u7f16\u53f7\uff1aTPS375
\u7b2c\u4e00\u4f5c\u8005\uff1aDr. Nashat Y. Gabrail<\/span><\/span><\/p>\n

\u56fd\u9645\u80c3\u764c\u5927\u4f1a\uff08IGCC\uff09<\/span>
\u6458\u8981\u6807\u9898\uff1aA Phase I Study of TST001 (anti-Claudin18.2 monoclonal antibody) in Patients with Solid Tumors
TST001\uff08\u6297Claudin18.2\u5355\u514b\u9686\u6297\u4f53\uff09\u5728\u5b9e\u4f53\u7624\u60a3\u8005\u4e2d\u7684I\u671f\u4e34\u5e8a\u7814\u7a76
\u77f3\u660e\uff0c\u674e\u5b81\uff0c\u9f9a\u7ee7\u82b3\uff0c\u5f20\u5251\uff0c\u5f90\u519c\uff0c\u5f20\u6dfc, \u9f50\u957f\u677e\uff0c\u590f\u632f\u4e2d\uff0c\u6c88\u96e8\uff0c\u738b\u5efa\u660e\uff0c\u5f90\u8389\uff0c\u621a\u5ddd\uff0c\u94b1\u96ea\u660e\uff0c\u6c88\u7433
\u6458\u8981\u7f16\u53f7\uff1aIGCC22-ABS-1152
\u7b2c\u4e00\u4f5c\u8005\uff1a\u77f3\u660e\u535a\u58eb<\/p>\n

TST001\u662f\u521b\u80dc\u96c6\u56e2\u81ea\u4e3b\u7814\u53d1\u7684\u9ad8\u4eb2\u548c\u529b\u4eba\u6e90\u5316\u6297\u4f53\u3002\u5176\u9488\u5bf9\u8868\u8fbeClaudin18.2\u7684\u80bf\u7624\u7ec6\u80de\u663e\u793a\u51fa\u5f3a\u5927\u7684ADCC\u4f53\u5916\u6d3b\u6027\uff0c\u5e76\u4e14\u5728\u4e2d\u9ad8\u8868\u8fbeClaudin18.2\u7684\u80bf\u7624\u6a21\u578b\u4e2d\u62e5\u6709\u826f\u597d\u7684\u6297\u80bf\u7624\u6d3b\u6027\u3002TST001\u7684I\u671f\u4e34\u5e8a\u7814\u7a76\u81ea2020\u5e744\u6708\u8d77\u5728\u4e2d\u7f8e\u4e24\u5730\u540c\u65f6\u5f00\u5c55\u3002<\/p>\n

TST001\u5df2\u5b8c\u6210\u4e2d\u56fd\u4e34\u5e8a\u7814\u7a76\u7684\u5242\u91cf\u9012\u589e\u9636\u6bb5\uff0c\u76ee\u524d\u6b63\u5728\u8868\u8fbeClaudin18.2\u7684\u591a\u79cd\u80bf\u7624\u7c7b\u578b\uff08\u5305\u62ec\u80c3\/\u80c3\u98df\u7ba1\u8fde\u63a5\u90e8\u764c\u3001\u80f0\u817a\u764c\u4ee5\u53ca\u5176\u4ed6\u51e0\u79cd\u80bf\u7624\u7c7b\u578b\uff09\u60a3\u8005\u4e2d\u8fdb\u884cIb\/IIa\u671f\u5355\u836f\u6cbb\u7597\u8bd5\u9a8c\u3002\u6b64\u5916\uff0cTST001\u4e0e\u5316\u7597\u6216PD-1\u8054\u7528\u7528\u4e8e\u4e00\u7ebf\u53ca\u65e2\u5f80\u63a5\u53d7\u8fc7\u6cbb\u7597\u7684\u80c3\/\u80c3\u98df\u7ba1\u8fde\u63a5\u90e8\u764c\u60a3\u8005\u7684\u4e34\u5e8a\u8bd5\u9a8c\u4e5f\u5728\u8fdb\u884c\u4e4b\u4e2d\u3002IGCC\u6d77\u62a5\u5c06\u5c55\u793a\u8be5\u8bd5\u9a8c\u5242\u91cf\u9012\u589e\u90e8\u5206\u7684\u6570\u636e\u3002<\/p>\n

TST001\u7684\u7f8e\u56fd\u7814\u7a76\u5373\u5c06\u5b8c\u6210\u5242\u91cf\u9012\u589e\u9636\u6bb5\uff0c\u5e76\u5c06\u5728\u8868\u8fbeClaudin18.2\u7684\u764c\u75c7\u60a3\u8005\u4e2d\u8fdb\u884c\u5242\u91cf\u6269\u5c55\u7814\u7a76\u3002\u5242\u91cf\u6269\u5c55\u7814\u7a76\u5c06\u5206\u4e3aTST001\u5355\u836f\u6cbb\u7597\u591a\u79cd\u80bf\u7624\u7c7b\u578b\u60a3\u8005\u548c\u4e0ePD-1\u6291\u5236\u5242\u8054\u7528\u6cbb\u7597\u80c3\/\u80c3\u98df\u7ba1\u8fde\u63a5\u90e8\u764c\u60a3\u8005\u3002ASCO GI\u6d77\u62a5TPS375\u5c06\u5c55\u793a\u7f8e\u56fd\u4e34\u5e8a\u7814\u7a76\u8bbe\u8ba1\u3002<\/p>\n

\u201cClaudin18.2<\/span>\u7684\u751f\u7269\u5b66\u7279\u6027\u8868\u660e\u5b83\u662f\u4e00\u79cd\u7406\u60f3\u7684\u80bf\u7624\u836f\u7269\u6cbb\u7597\u9776\u70b9\u3002\u201d\u521b\u80dc\u96c6\u56e2\u5168\u7403\u7814\u53d1\u6267\u884c\u526f\u603b\u88c1\u517c\u9996\u5e2d\u533b\u5b66\u5b98\u77f3\u660e\u535a\u58eb\u8868\u793a\uff0c\u201c\u73b0\u6709\u5242\u91cf\u6570\u636e\u8868\u660eTST001<\/span>\u4e0d\u7ba1\u662f\u5355\u836f\u6216\u8054\u5408\u5747\u662f\u5b89\u5168\u7684\u3002\u6b64\u524d\uff0cTST001\u4e5f\u5df2\u83b7\u5f97FDA\u7684\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\uff0c\u5c06\u7528\u4e8e\u6cbb\u7597\u80c3\u764c\u53ca\u80c3\u98df\u7ba1\u8fde\u63a5\u90e8\u764c\u3002\u6211\u4eec\u975e\u5e38\u671f\u5f85TST001\u8054\u5408\u5316\u7597\u548c\/\u6216PD-1\u7684\u7814\u7a76\u80fd\u5728\u672a\u6765\u7ed9\u5e7f\u5927\u80c3\u764c\u60a3\u8005\u5e26\u6765\u65b0\u7684\u66f4\u6709\u6548\u7684\u6cbb\u7597\u9009\u62e9\u3002\u201d<\/p>\n

\u5173\u4e8eTST001<\/b><\/p>\n

TST001\u662f\u4e00\u79cd\u9ad8\u4eb2\u548c\u529b\u7684\u9776\u5411Claudin18.2\u7684\u4eba\u6e90\u5316\u5355\u514b\u9686\u6297\u4f53\uff0c\u5177\u6709\u589e\u5f3a\u7684ADCC\u548cCDC\u6d3b\u6027\uff0c\u5728\u5f02\u79cd\u79fb\u690d\u8bd5\u9a8c\u4e2d\u663e\u793a\u51fa\u5f3a\u5927\u7684\u6297\u80bf\u7624\u6d3b\u6027\u3002\u8be5\u836f\u7269\u662f\u5168\u7403\u8303\u56f4\u5185\u5f00\u53d1\u7684\u7b2c\u4e8c\u4e2aClaudin18.2\u9776\u5411\u6297\u4f53\u6cbb\u7597\u5019\u9009\u836f\u7269\uff0c\u7531\u521b\u80dc\u96c6\u56e2\u901a\u8fc7\u5176\u72ec\u7acb\u5f00\u53d1\u7684\u514d\u75ab\u8010\u53d7\u7a81\u7834(IMTB)\u6280\u672f\u5e73\u53f0\u5f00\u53d1\u3002TST001\u901a\u8fc7\u6297\u4f53\u4f9d\u8d56\u6027\u7ec6\u80de\u6bd2\u6027(ADCC)\u548c\u8865\u4f53\u4f9d\u8d56\u6027\u7ec6\u80de\u6bd2\u6027(CDC)\u673a\u5236\u6740\u6b7b\u8868\u8fbeClaudin18.2\u7684\u80bf\u7624\u7ec6\u80de\u3002\u5229\u7528\u5148\u8fdb\u7684\u751f\u7269\u52a0\u5de5\u6280\u672f\uff0cTST001\u7684\u5ca9\u85fb\u7cd6\u542b\u91cf\u5728\u751f\u4ea7\u8fc7\u7a0b\u4e2d\u5927\u5927\u964d\u4f4e\uff0c\u8fdb\u4e00\u6b65\u589e\u5f3a\u4e86TST001\u7684NK\u7ec6\u80de\u4ecb\u5bfc\u7684\u80bf\u7624\u6740\u4f24\u6d3b\u6027\u3002\u81ea2020\u5e748\u6708\u4ee5\u6765\uff0c\u4e2d\u56fd\u548c\u7f8e\u56fd\u5747\u4e00\u76f4\u5728\u8fdb\u884cTST001\u7684\u4e34\u5e8a\u8bd5\u9a8c(NCT04396821, NCT04495296\/CTR20201281)\u3002\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40(FDA)\u5df2\u6388\u4e88TST001\u7528\u4e8e\u6cbb\u7597\u80c3\u764c\u53ca\u80c3\u98df\u7ba1\u8fde\u63a5\u90e8\u764c\u7684\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\u3002<\/p>\n

\u5173\u4e8e\u521b\u80dc\u96c6\u56e2<\/b><\/p>\n

\u521b\u80dc\u96c6\u56e2\u662f\u4e00\u5bb6\u4e34\u5e8a\u9636\u6bb5\u7684\u5728\u751f\u7269\u836f\u53d1\u73b0\u3001\u7814\u53d1\u3001\u5de5\u827a\u5f00\u53d1\u548c\u751f\u4ea7\u65b9\u9762\u5177\u6709\u5168\u9762\u7efc\u5408\u80fd\u529b\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002<\/p>\n

\u521b\u80dc\u96c6\u56e2\u603b\u90e8\u4f4d\u4e8e\u82cf\u5dde\uff0c\u5df2\u6210\u529f\u642d\u5efa\u4e86\u5168\u7403\u7684\u4e1a\u52a1\u5e03\u5c40\uff1a\u5728\u82cf\u5dde\u8bbe\u6709\u836f\u7269\u53d1\u73b0\u3001\u4e34\u5e8a\u548c\u8f6c\u5316\u7814\u7a76\u4e2d\u5fc3\uff0c\u521b\u80dc\u96c6\u56e2\u603b\u90e8\u53ca\u4ee5\u8fde\u7eed\u704c\u6d41\u751f\u4ea7\u5de5\u827a\u4e3a\u6838\u5fc3\u6280\u672f\u7684\u751f\u4ea7\u57fa\u5730\u4e5f\u6b63\u5728\u5efa\u8bbe\u4e2d\u3002\u5728\u676d\u5dde\u62e5\u6709\u5de5\u827a\u4e0e\u4ea7\u54c1\u5f00\u53d1\u4e2d\u5fc3\u4ee5\u53ca\u836f\u7269\u751f\u4ea7\u57fa\u5730\uff0c\u5728\u5317\u4eac\u3001\u4e0a\u6d77\u3001\u5e7f\u5dde\u548c\u7f8e\u56fd\u666e\u6797\u65af\u987f\u5206\u522b\u8bbe\u6709\u4e34\u5e8a\u5f00\u53d1\u4e2d\u5fc3\uff0c\u5e76\u5728\u7f8e\u56fd\u6ce2\u58eb\u987f\u3001\u6d1b\u6749\u77f6\u8bbe\u7acb\u4e86\u5bf9\u5916\u5408\u4f5c\u4e2d\u5fc3\u3002\u521b\u80dc\u96c6\u56e2\u7684\u5f00\u53d1\u7ba1\u7ebf\u5df2\u6709\u5341\u4e2a\u6cbb\u7597\u7528\u6297\u4f53\u65b0\u836f\u5206\u5b50\uff0c\u6db5\u76d6\u80bf\u7624\u3001\u9aa8\u79d1\u548c\u80be\u75c5\u7b49\u9886\u57df\u3002<\/p>\n

\u5982\u9700\u4e86\u89e3\u5173\u4e8e\u521b\u80dc\u96c6\u56e2\u7684\u66f4\u591a\u4fe1\u606f\uff0c\u8bf7\u8bbf\u95ee\u516c\u53f8\u7f51\u7ad9\uff1awww.transcenta.com<\/a> \u6216\u9886\u82f1\u8d26\u53f7\uff1aTranscenta\u3002<\/p>\n

\u524d\u77bb\u6027\u58f0\u660e<\/b><\/p>\n

\u672c\u65b0\u95fb\u7a3f\u6240\u53d1\u5e03\u7684\u4fe1\u606f\u4e2d\u53ef\u80fd\u4f1a\u5305\u542b\u67d0\u4e9b\u524d\u77bb\u6027\u8868\u8ff0\u3002\u8fd9\u4e9b\u8868\u8ff0\u672c\u8d28\u4e0a\u5177\u6709\u76f8\u5f53\u98ce\u9669\u548c\u4e0d\u786e\u5b9a\u6027\u3002\u5728\u4f7f\u7528\u201c\u9884\u671f\u201d\u3001\u201c\u76f8\u4fe1\u201d\u3001\u201c\u9884\u6d4b\u201d\u3001\u201c\u671f\u671b\u201d\u3001\u201c\u6253\u7b97\u201d\u53ca\u5176\u4ed6\u7c7b\u4f3c\u8bcd\u8bed\u8fdb\u884c\u8868\u8ff0\u65f6\uff0c\u51e1\u4e0e\u672c\u516c\u53f8\u6709\u5173\u7684\uff0c\u76ee\u7684\u5747\u662f\u8981\u6307\u660e\u5176\u5c5e\u524d\u77bb\u6027\u8868\u8ff0\u3002\u672c\u516c\u53f8\u5e76\u65e0\u4e49\u52a1\u4e0d\u65ad\u5730\u66f4\u65b0\u8fd9\u4e9b\u9884\u6d4b\u6027\u9648\u8ff0\u3002<\/p>\n

\u8fd9\u4e9b\u524d\u77bb\u6027\u8868\u8ff0\u4e43\u57fa\u4e8e\u672c\u516c\u53f8\u7ba1\u7406\u5c42\u5728\u505a\u51fa\u8868\u8ff0\u65f6\u5bf9\u672a\u6765\u4e8b\u52a1\u7684\u73b0\u6709\u770b\u6cd5\u3001\u5047\u8bbe\u3001\u671f\u671b\u3001\u4f30\u8ba1\u3001\u9884\u6d4b\u548c\u7406\u89e3\u3002\u8fd9\u4e9b\u8868\u8ff0\u5e76\u975e\u5bf9\u672a\u6765\u53d1\u5c55\u7684\u4fdd\u8bc1\uff0c\u4f1a\u53d7\u5230\u98ce\u9669\u3001\u4e0d\u786e\u6027\u53ca\u5176\u4ed6\u56e0\u7d20\u7684\u5f71\u54cd\uff0c\u6709\u4e9b\u4e43\u8d85\u51fa\u672c\u516c\u53f8\u7684\u63a7\u5236\u8303\u56f4\uff0c\u96be\u4ee5\u9884\u8ba1\u3002\u56e0\u6b64\uff0c\u53d7\u6211\u4eec\u7684\u4e1a\u52a1\u3001\u7ade\u4e89\u73af\u5883\u3001\u653f\u6cbb\u3001\u7ecf\u6d4e\u3001\u6cd5\u5f8b\u548c\u793e\u4f1a\u60c5\u51b5\u7684\u672a\u6765\u53d8\u5316\u53ca\u53d1\u5c55\u7684\u5f71\u54cd\uff0c\u5b9e\u9645\u7ed3\u679c\u53ef\u80fd\u4f1a\u4e0e\u524d\u77bb\u6027\u8868\u8ff0\u6240\u542b\u8d44\u6599\u6709\u8f83\u5927\u5dee\u522b\u3002<\/p>\n

\u66f4\u591a\u4fe1\u606f\uff0c\u656c\u8bf7\u8054\u7cfb<\/b><\/p>\n

\u6295\u8d44\u8005\u5173\u7cfb\uff1air@transcenta.com<\/a>
\u5a92\u4f53\u8054\u7cfb\uff1apr@transcenta.com<\/a>
\u5546\u52a1\u5408\u4f5c\uff1abd@transcenta.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

\u82cf\u5dde2022\u5e741\u670812\u65e5 \/\u7f8e\u901a\u793e\/ — \u521b\u80dc\u96c6\u56e2\uff0806628.HK\uff09\uff0c\u4e00\u5bb6\u5177\u5907\u751f\u7269\u836f\u53d1\u73b0\u3001\u7814\u53d1\u3001\u5de5\u827a\u5f00\u53d1\u548c\u751f\u4ea7\u5168\u6d41\u7a0b\u6574\u5408\u80fd\u529b\u7684\u4e34\u5e8a\u9636\u6bb5\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\uff0c\u5ba3\u5e03TST001\u7f8e\u56fdI\u671f\u4e34\u5e8a\u8bd5\u9a8c\u5c06\u4e8e2022\u5e741\u670820-22\u65e5\u5728\u65e7\u91d1\u5c71\u4e3e\u529e\u7684\u7f8e\u56fd\u4e34\u5e8a\u80bf\u7624\u5b66\u4f1a\u80c3\u80a0\u9053\u80bf\u7624\u7814\u8ba8\u4f1a(ASCO GI)\u4e0a\u901a\u8fc7Trial in Progress (TiP) \u6d77\u62a5\u7684\u65b9\u5f0f\u5c55\u793a\u3002TST001\u4e2d\u56fdI\u671f\u4e34\u5e8a\u6570\u636e\u5c06\u4e8e2022\u5e743\u67086-9\u65e5\u5728\u4f11\u65af\u987f\u4e3e\u529e\u7684\u56fd\u9645\u80c3\u764c\u5927\u4f1a\uff08IGCC\uff09\u4e0a\u4ee5\u6d77\u62a5\u7684\u5f62\u5f0f\u516c\u5e03\u3002 \u6d77\u62a5\u5c55\u793a\u7f8e\u56fd\u4e34\u5e8a\u80bf\u7624\u5b66\u4f1a\u80c3\u80a0\u9053\u80bf\u7624\u7814\u8ba8\u4f1a\uff08ASCO GI\uff09\u6458\u8981\u6807\u9898\uff1aA Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of TST001 in Patients with Locally Advanced or Metastatic Solid Tumors\u4e00\u9879\u5728\u5c40\u90e8\u665a\u671f\u6216\u8f6c\u79fb\u6027\u5b9e\u4f53\u7624\u60a3\u8005\u4e2d\u8bc4\u4f30TST001\u5b89\u5168\u6027\u3001\u8010\u53d7\u6027\u548c\u836f\u4ee3\u52a8\u529b\u5b66\u7684I\u671f\u4e34\u5e8a\u8bd5\u9a8c\u6458\u8981\u7f16\u53f7\uff1aTPS375\u7b2c\u4e00\u4f5c\u8005\uff1aDr. Nashat Y. Gabrail \u56fd\u9645\u80c3\u764c\u5927\u4f1a\uff08IGCC\uff09\u6458\u8981\u6807\u9898\uff1aA Phase I Study of TST001 (anti-Claudin18.2 monoclonal antibody) in Patients with Solid TumorsTST001\uff08\u6297Claudin18.2\u5355\u514b\u9686\u6297\u4f53\uff09\u5728\u5b9e\u4f53\u7624\u60a3\u8005\u4e2d\u7684I\u671f\u4e34\u5e8a\u7814\u7a76\u77f3\u660e\uff0c\u674e\u5b81\uff0c\u9f9a\u7ee7\u82b3\uff0c\u5f20\u5251\uff0c\u5f90\u519c\uff0c\u5f20\u6dfc, \u9f50\u957f\u677e\uff0c\u590f\u632f\u4e2d\uff0c\u6c88\u96e8\uff0c\u738b\u5efa\u660e\uff0c\u5f90\u8389\uff0c\u621a\u5ddd\uff0c\u94b1\u96ea\u660e\uff0c\u6c88\u7433\u6458\u8981\u7f16\u53f7\uff1aIGCC22-ABS-1152\u7b2c\u4e00\u4f5c\u8005\uff1a\u77f3\u660e\u535a\u58eb TST001\u662f\u521b\u80dc\u96c6\u56e2\u81ea\u4e3b\u7814\u53d1\u7684\u9ad8\u4eb2\u548c\u529b\u4eba\u6e90\u5316\u6297\u4f53\u3002\u5176\u9488\u5bf9\u8868\u8fbeClaudin18.2\u7684\u80bf\u7624\u7ec6\u80de\u663e\u793a\u51fa\u5f3a\u5927\u7684ADCC\u4f53\u5916\u6d3b\u6027\uff0c\u5e76\u4e14\u5728\u4e2d\u9ad8\u8868\u8fbeClaudin18.2\u7684\u80bf\u7624\u6a21\u578b\u4e2d\u62e5\u6709\u826f\u597d\u7684\u6297\u80bf\u7624\u6d3b\u6027\u3002TST001\u7684I\u671f\u4e34\u5e8a\u7814\u7a76\u81ea2020\u5e744\u6708\u8d77\u5728\u4e2d\u7f8e\u4e24\u5730\u540c\u65f6\u5f00\u5c55\u3002 TST001\u5df2\u5b8c\u6210\u4e2d\u56fd\u4e34\u5e8a\u7814\u7a76\u7684\u5242\u91cf\u9012\u589e\u9636\u6bb5\uff0c\u76ee\u524d\u6b63\u5728\u8868\u8fbeClaudin18.2\u7684\u591a\u79cd\u80bf\u7624\u7c7b\u578b\uff08\u5305\u62ec\u80c3\/\u80c3\u98df\u7ba1\u8fde\u63a5\u90e8\u764c\u3001\u80f0\u817a\u764c\u4ee5\u53ca\u5176\u4ed6\u51e0\u79cd\u80bf\u7624\u7c7b\u578b\uff09\u60a3\u8005\u4e2d\u8fdb\u884cIb\/IIa\u671f\u5355\u836f\u6cbb\u7597\u8bd5\u9a8c\u3002\u6b64\u5916\uff0cTST001\u4e0e\u5316\u7597\u6216PD-1\u8054\u7528\u7528\u4e8e\u4e00\u7ebf\u53ca\u65e2\u5f80\u63a5\u53d7\u8fc7\u6cbb\u7597\u7684\u80c3\/\u80c3\u98df\u7ba1\u8fde\u63a5\u90e8\u764c\u60a3\u8005\u7684\u4e34\u5e8a\u8bd5\u9a8c\u4e5f\u5728\u8fdb\u884c\u4e4b\u4e2d\u3002IGCC\u6d77\u62a5\u5c06\u5c55\u793a\u8be5\u8bd5\u9a8c\u5242\u91cf\u9012\u589e\u90e8\u5206\u7684\u6570\u636e\u3002 TST001\u7684\u7f8e\u56fd\u7814\u7a76\u5373\u5c06\u5b8c\u6210\u5242\u91cf\u9012\u589e\u9636\u6bb5\uff0c\u5e76\u5c06\u5728\u8868\u8fbeClaudin18.2\u7684\u764c\u75c7\u60a3\u8005\u4e2d\u8fdb\u884c\u5242\u91cf\u6269\u5c55\u7814\u7a76\u3002\u5242\u91cf\u6269\u5c55\u7814\u7a76\u5c06\u5206\u4e3aTST001\u5355\u836f\u6cbb\u7597\u591a\u79cd\u80bf\u7624\u7c7b\u578b\u60a3\u8005\u548c\u4e0ePD-1\u6291\u5236\u5242\u8054\u7528\u6cbb\u7597\u80c3\/\u80c3\u98df\u7ba1\u8fde\u63a5\u90e8\u764c\u60a3\u8005\u3002ASCO GI\u6d77\u62a5TPS375\u5c06\u5c55\u793a\u7f8e\u56fd\u4e34\u5e8a\u7814\u7a76\u8bbe\u8ba1\u3002… Read More<\/a><\/p>\n","protected":false},"author":556,"featured_media":8278,"comment_status":"close","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1965],"tags":[],"class_list":["post-59766","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-partnerships"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/59766","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/comments?post=59766"}],"version-history":[{"count":1,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/59766\/revisions"}],"predecessor-version":[{"id":59767,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/59766\/revisions\/59767"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media\/8278"}],"wp:attachment":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media?parent=59766"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/categories?post=59766"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/tags?post=59766"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}